UroGen Pharma Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| UR8.F | PHM.VI | QURE | CGON | OCUL | RARE | |
|---|---|---|---|---|---|---|
| Market cap | 1.22B | 1.16B | 1.60B | 6.00B | 1.57B | 1.69B |
| P/E (TTM) | — | 17.1 | — | — | — | — |
| Forward P/E | -6.8 | — | -7.8 | -22.4 | -4.8 | 76.1 |
| Price/book | -12.9 | 4.9 | 7.2 | 5.8 | 3.0 | -5.8 |
| Dividend yield | — | 1.49% | — | — | — | — |
| 1-year change | +80.89% | −7.02% | −8.40% | +70.60% | −32.83% | −44.56% |
| Today | −16.49% | +0.22% | −3.52% | +5.70% | +4.69% | +3.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All UR8.F news ›UroGen Pharma GAAP EPS of -$0.03 misses by $0.13, revenue of $89M misses by $0.91M
UroGen Pharma Q3 results: EPS missed and revenue rose 223.9% year over year to $89M. - UroGen Pharma press release (URGN): Q3 GAAP EPS of -$0.03 misses by $0.13. - Revenue of $89M (+223.9% Y/Y) misses by $0.91M. - 1,538 activated sites of…
UroGen Pharma Q3 revenue misses expectations on JELMYTO decline
TradingView UroGen Pharma Q3 revenue misses expectations on JELMYTO decline
UroGen Pharma management to meet with Oppenheimer
Meeting to be held in San Francisco on October 20, in Los Angeles on October 21-22 and Denver on October 23 hosted by Oppenheimer. Published fi... UroGen Pharma management to meet with Oppenheimer Meeting to be held in San Francisco on…
UroGen Pharma announces FDA acceptance of UGN-103 NDA
UroGen Pharma (URGN) announced FDA acceptance of the new drug application, or NDA, for investigational drug UGN-103 for intravesical solution fo... UroGen Pharma announces FDA acceptance of UGN-103 NDA UroGen Pharma (URGN) announced FDA…
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd.
INTRAGEL THERAPEUTICS LTD announced that it entered into an Investment Agreement for gross proceeds of $7,000,000 on August 20, 2026. The transaction included participation from new investor, UroGen... Published on 08/20/2026 at 10:05 am…
Transcript : UroGen Pharma Ltd., Q2 2026 Earnings Call, Aug 05, 2026
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to the UroGen Pharma's Q2 2026 Earnings Conference Call. [Operator Instructions] Please be advised that Transcript : UroGen Pharma Ltd., Q2 2026…
UroGen Pharma Ltd.: Relative Strength Chart - Stock Nasdaq
Compare UroGen Pharma Ltd. with the company of your choice via a Relative Strength chart. Real-time URGN price, Nasdaq stock exchange Relative Strength Chart UroGen Pharma Ltd. Biotechnology & Medical Research All financial news and data…
Urogen Pharma (NASDAQ:URGN) Given “Buy” Rating at HC Wainwright
Posted by Danessa Lincoln on Oct 19th, 2026 Urogen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a…
Urogen Pharma (NASDAQ:URGN) Stock Rated “Moderate Buy” by Wall Street Brokerages
Posted by Kim Johansen on Oct 19th, 2026 Check Out Our Latest Stock Report on Urogen Pharma Shares of NASDAQ URGN opened at $34.56 on Monday. Urogen Pharma has a twelve month low of $16.36 and a twelve month high of $50.81. The stock has a…
UroGen Pharma: An Emerging GARP Stock
UroGen Pharma (URGN) stock dipped 30% after a 208% rally—see why Zusduri’s launch, reimbursement, and patents could fuel growth. - UroGen Pharma has pulled back 30% after a 208% rally, driven by Zusduri’s strong launch as the only approved…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com7
- marketscreener.com5
- markets.businessinsider.com2
- seekingalpha.com2
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.